InflaRx N : Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 - Form 6-K

IFRX

Disclaimer

Inflarx NV published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 11:41:02 UTC.